Health
Health News
Apollo Medical Holdings, Inc. Announces Purchase of Controlling Interests in Sun Clinical Laboratories
Apollo Medical Holdings, Inc. Announces Purchase of Controlling Interests in Sun Clinical Laboratories PR Newswire ALHAMBRA, Calif., June 2, 2021...
Read moreNLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021
NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021 PR Newswire STANS, Switzerland, June...
Read morePoseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders PR Newswire SAN DIEGO, June 2, 2021 SAN DIEGO, June 2,...
Read moreArchCare Extends Contract with Tabula Rasa HealthCare for Medication Safety, Efficacy, and Adherence Services
ArchCare Extends Contract with Tabula Rasa HealthCare for Medication Safety, Efficacy, and Adherence Services PR Newswire MOORESTOWN, N.J., June 2,...
Read morePharmAbcine to Present at the BIO Digital International Convention 2021
PharmAbcine to Present at the BIO Digital International Convention 2021 PR Newswire DAEJEON, South Korea, June 2, 2021 DAEJEON, South...
Read moreI-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab PR Newswire...
Read moreKintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021 PR Newswire SAN DIEGO, June...
Read moreAbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021...
Read morePhase 3 Maintenance Results Show Patients with Crohn’s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year
Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One...
Read moreDocGo to Participate at the Stifel 2021 Virtual Cross Sector Insight Conference
DocGo to Participate at the Stifel 2021 Virtual Cross Sector Insight Conference PR Newswire NEW YORK, June 2, 2021 NEW...
Read more